Top

Published in:

Open Access 01-10-2016 | Molecular Imaging (J Wu and P Nguyen, Section Editors)

Molecular Imaging of Angiogenesis in Cardiac Regeneration

Authors: Ljubica Mandic, Denise Traxler, Alfred Gugerell, Katrin Zlabinger, Dominika Lukovic, Noemi Pavo, Georg Goliasch, Andreas Spannbauer, Johannes Winkler, Mariann Gyöngyösi

Published in: Current Cardiovascular Imaging Reports | Issue 10/2016

Abstract

Purpose of Review

Myocardial infarction (MI) leading to heart failure displays an important cause of death worldwide. Adequate restoration of blood flow to prevent this transition is a crucial factor to improve long-term morbidity and mortality. Novel regenerative therapies have been thoroughly investigated within the past decades.

Recent Findings

Increased angiogenesis in infarcted myocardium has shown beneficial effects on the prognosis of MI; therefore, the proangiogenic capacity of currently tested treatments is of specific interest. Molecular imaging to visualize formation of new blood vessels in vivo displays a promising option to monitor proangiogenic effects of regenerative substances.

Summary

Based on encouraging results in preclinical models, molecular angiogenesis imaging has recently been applied in a small set of patients. This article reviews recent literature on noninvasive in vivo molecular imaging of angiogenesis after MI as an integral part of cardiac regeneration.

Cochain C, Channon KM, Silvestre JS. Angiogenesis in the infarcted myocardium. Antioxid Redox Signal. 2013;18(9):1100–13. doi:10.1089/ars.2012.4849.PubMedPubMedCentralCrossRef

Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet. 2011;378(9792):704–12. doi:10.1016/S0140-6736(11)60894-5.PubMedPubMedCentralCrossRef

Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med. 1995;73(7):333–46.PubMedCrossRef

Meoli DF, Sadeghi MM, Krassilnikova S, Bourke BN, Giordano FJ, Dione DP, et al. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest. 2004;113(12):1684–91. doi:10.1172/JCI20352.PubMedPubMedCentralCrossRef

Uchida Y, Yanagisawa-Miwa A, Nakamura F, Yamada K, Tomaru T, Kimura K, et al. Angiogenic therapy of acute myocardial infarction by intrapericardial injection of basic fibroblast growth factor and heparin sulfate: an experimental study. Am Heart J. 1995;130(6):1182–8.PubMedCrossRef

Gyöngyösi M, Wojakowski W, Lemarchand P, Lunde K, Tendera M, Bartunek J, et al. Meta-analysis of cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res. 2015. doi:10.1161/circresaha.116.304346.PubMedPubMedCentral

Scimia MC, Gumpert AM, Koch WJ. Cardiovascular gene therapy for myocardial infarction. Expert Opin Biol Ther. 2014;14(2):183–95. doi:10.1517/14712598.2014.866085.PubMedCrossRef

Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146(6):873–87. doi:10.1016/j.cell.2011.08.039.PubMedCrossRef

Dissoki S, Abourbeh G, Salnikov O, Mishani E, Jacobson O. PET molecular imaging of angiogenesis with a multiple tyrosine kinase receptor-targeted agent in a rat model of myocardial infarction. Mol Imaging Biol. 2015;17(2):222–30. doi:10.1007/s11307-014-0790-8.PubMedCrossRef

10.

Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307. doi:10.1038/nature10144.PubMedPubMedCentralCrossRef

11.

Frangogiannis NG. The mechanistic basis of infarct healing. Antioxid Redox Signal. 2006;8(11-12):1907–39. doi:10.1089/ars.2006.8.1907.PubMedCrossRef

12.

Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35(3):569–82.PubMedCrossRef

13.

Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005;115(8):2108–18. doi:10.1172/JCI24682.PubMedPubMedCentralCrossRef

14.

Silvestre JS, Smadja DM, Levy BI. Postischemic revascularization: from cellular and molecular mechanisms to clinical applications. Physiol Rev. 2013;93(4):1743–802. doi:10.1152/physrev.00006.2013.PubMedCrossRef

15.

Jivraj N, Phinikaridou A, Shah AM, Botnar RM. Molecular imaging of myocardial infarction. Basic Res Cardiol. 2014;109(1):397. doi:10.1007/s00395-013-0397-2.PubMedCrossRef

16.

Stacy MR, Sinusas AJ. Emerging imaging modalities in regenerative medicine. Curr Pathobiol Rep. 2015;3(1):27–36. doi:10.1007/s40139-015-0073-3.CrossRef

17.

Ripa RS, Kjaer A. Imaging atherosclerosis with hybrid positron emission tomography/magnetic resonance imaging. Biomed Res Int. 2015;2015:914516. doi:10.1155/2015/914516.PubMedPubMedCentralCrossRef

18.

Stacy MR, Maxfield MW, Sinusas AJ. Targeted molecular imaging of angiogenesis in PET and SPECT: a review. Yale J Biol Med. 2012;85(1):75–86.PubMedPubMedCentral

19.

Naumova AV, Modo M, Moore A, Murry CE, Frank JA. Clinical imaging in regenerative medicine. Nat Biotechnol. 2014;32(8):804–18. doi:10.1038/nbt.2993.PubMedPubMedCentralCrossRef

20.•

Cai M, Ren L, Yin X, Guo Z, Li Y, He T, Tang Y, Long T, Liu Y, Liu G, Zhang X, Hu S. PET monitoring angiogenesis of infarcted myocardium after treatment with vascular endothelial growth factor and bone marrow mesenchymal stem cells. Amino Acids. 2016; 48(3):811-820. doi:10.1007/s00726-015-2129-4. This experimental rat myocardial infarction model introduces a new ¹⁸ F based radiotracer for angiogenesis imaging which offers a variety of advantages over previous radiotracers. Moreover, ¹⁸ F-Alfatide II was used to demonstrate increased myocardial angiogenesis in rats treated with VEGF and/or BMSCs.

21.

Li X, Heber D, Rausch I, Beitzke D, Mayerhoefer ME, Rasul S, et al. Quantitative assessment of atherosclerotic plaques on F-FDG PET/MRI: comparison with a PET/CT hybrid system. Eur J Nucl Med Mol Imaging. 2016. doi:10.1007/s00259-016-3308-6.

22.

Ratib O, Nkoulou R. Potential applications of PET/MR imaging in cardiology. J Nucl Med. 2014;55(Supplement 2):40S–6. doi:10.2967/jnumed.113.129262.PubMedCrossRef

23.

Stacy MR, Paeng JC, Sinusas AJ. The role of molecular imaging in the evaluation of myocardial and peripheral angiogenesis. Ann Nucl Med. 2015;29(3):217–23. doi:10.1007/s12149-015-0961-y.PubMedPubMedCentralCrossRef

24.

Lee JS, Kim JH. Recent advances in hybrid molecular imaging systems. Semin Musculoskelet Radiol. 2014;18(2):103–22. doi:10.1055/s-0034-1371014.PubMedCrossRef

25.

Constantine G, Shan K, Flamm SD, Sivananthan MU. Role of MRI in clinical cardiology. Lancet. 2004;363(9427):2162–71. doi:10.1016/S0140-6736(04)16509-4.PubMedCrossRef

26.

Mulder WJ, Strijkers GJ, Habets JW, Bleeker EJ, van der Schaft DW, Storm G, et al. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J. 2005;19(14):2008–10. doi:10.1096/fj.05-4145fje.PubMed

27.

Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, et al. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med. 2005;53(3):621–7. doi:10.1002/mrm.20391.PubMedCrossRef

28.

Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 1998;4(5):623–6.PubMedCrossRef

29.

Zhang C, Jugold M, Woenne EC, Lammers T, Morgenstern B, Mueller MM, et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 2007;67(4):1555–62. doi:10.1158/0008-5472.CAN-06-1668.PubMedCrossRef

30.

Leung K. Cyclo(Arg-Gly-Asp-D-Try-Glu) conjugated to ultrasmall superparamagnetic iron oxide nanoparticles. Bethesda (MD): Molecular Imaging and Contrast Agent Database (MICAD); 2004.

31.

Yang Y, Yang Y, Yanasak N, Schumacher A, Hu TC. Temporal and noninvasive monitoring of inflammatory-cell infiltration to myocardial infarction sites using micrometer-sized iron oxide particles. Magn Reson Med. 2010;63(1):33–40. doi:10.1002/mrm.22175.PubMed

32.

Singh N, Jenkins GJS, Asadi R, Doak SH. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Reviews. 2010; 1:10.3402/nano.v3401i3400.5358. doi:10.3402/nano.v1i0.5358.

33.

Smith AH, Fujii H, Kuliszewski MA, Leong-Poi H. Contrast ultrasound and targeted microbubbles: diagnostic and therapeutic applications for angiogenesis. J Cardiovasc Transl Res. 2011;4(4):404–15. doi:10.1007/s12265-011-9282-2.PubMedCrossRef

34.

Xie J, Liao Y, Yang L, Wu J, Liu C, Xuan W, et al. Ultrasound molecular imaging of angiogenesis induced by mutant forms of hypoxia-inducible factor-1alpha. Cardiovasc Res. 2011;92(2):256–66. doi:10.1093/cvr/cvr229.PubMedCrossRef

35.

Payen T, Dizeux A, Baldini C, Le Guillou-Buffello D, Lamuraglia M, Comperat E, et al. VEGFR2-targeted contrast-enhanced ultrasound to distinguish between two anti-angiogenic treatments. Ultrasound Med Biol. 2015;41(8):2202–11. doi:10.1016/j.ultrasmedbio.2015.04.010.PubMedCrossRef

36.

Kim JE, Kalimuthu S, Ahn BC. In vivo cell tracking with bioluminescence imaging. Nucl Med Mol Imaging. 2015;49(1):3–10. doi:10.1007/s13139-014-0309-x.PubMedCrossRef

37.

Baker M. Whole-animal imaging: the whole picture. Nature. 2010;463(7283):977–80. doi:10.1038/463977a.PubMedCrossRef

38.

Ahn BC. Applications of molecular imaging in drug discovery and development process. Curr Pharm Biotechnol. 2011;12(4):459–68.PubMedCrossRef

39.

Nguyen PK, Lan F, Wang Y, Wu JC. Imaging: guiding the clinical translation of cardiac stem cell therapy. Circ Res. 2011;109(8):962–79. doi:10.1161/CIRCRESAHA.111.242909.PubMedPubMedCentralCrossRef

40.

Blankstein R, Di Carli MF. Integration of coronary anatomy and myocardial perfusion imaging. Nat Rev Cardiol. 2010;7(4):226–36. doi:10.1038/nrcardio.2010.15.PubMedCrossRef

41.

Gaemperli O, Kaufmann PA, Alkadhi H. Cardiac hybrid imaging. Eur J Nucl Med Mol Imaging. 2014;41 Suppl 1:S91–103. doi:10.1007/s00259-013-2566-9.PubMedCrossRef

42.

Fricke E, Fricke H, Weise R, Kammeier A, Hagedorn R, Lotz N, et al. Attenuation correction of myocardial SPECT perfusion images with low-dose CT: evaluation of the method by comparison with perfusion PET. J Nucl Med. 2005;46(5):736–44.PubMed

43.

Brown ER, Kronmal RA, Bluemke DA, Guerci AD, Carr JJ, Goldin J, et al. Coronary calcium coverage score: determination, correlates, and predictive accuracy in the Multi-Ethnic Study of Atherosclerosis. Radiology. 2008;247(3):669–75. doi:10.1148/radiol.2473071469.PubMedCrossRef

44.

Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49(18):1860–70. doi:10.1016/j.jacc.2006.10.079.PubMedCrossRef

45.

Henzlova MJ, Duvall WL. The future of SPECT MPI: time and dose reduction. J Nucl Cardiol. 2011;18(4):580–7. doi:10.1007/s12350-011-9401-0.PubMedCrossRef

46.

Palyo R, Sinusas A, Liu YH. High-sensitivity and high-resolution SPECT/CT systems provide substantial dose reduction without compromising quantitative precision for assessment of myocardial perfusion or function. J Nucl Med. 2016. doi:10.2967/jnumed.115.164632.PubMed

47.

Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2014;383(9918):705–13. doi:10.1016/S0140-6736(13)61754-7.PubMedCrossRef

48.

Mazurek T, Kobylecka M, Zielenkiewicz M, Kurek A, Kochman J, Filipiak KJ, et al. PET/CT evaluation of F-FDG uptake in pericoronary adipose tissue in patients with stable coronary artery disease: Independent predictor of atherosclerotic lesions’ formation? J Nucl Cardiol. 2016. doi:10.1007/s12350-015-0370-6.PubMed

49.

Iagaru A, Gambhir SS. Imaging tumor angiogenesis: the road to clinical utility. AJR Am J Roentgenol. 2013;201(2):W183–91. doi:10.2214/AJR.12.8568.PubMedCrossRef

50.

Laitinen I, Notni J, Pohle K, Rudelius M, Farrell E, Nekolla SG, et al. Comparison of cyclic RGD peptides for alphavbeta3 integrin detection in a rat model of myocardial infarction. EJNMMI Res. 2013;3(1):38. doi:10.1186/2191-219x-3-38.PubMedPubMedCentralCrossRef

51.

Menichetti L, Kusmic C, Panetta D, Arosio D, Petroni D, Matteucci M, et al. MicroPET/CT imaging of alphavbeta(3) integrin via a novel (6)(8)Ga-NOTA-RGD peptidomimetic conjugate in rat myocardial infarction. Eur J Nucl Med Mol Imaging. 2013;40(8):1265–74. doi:10.1007/s00259-013-2432-9.PubMedCrossRef

52.•

Huang CC, Wei HJ, Lin KJ, Lin WW, Wang CW, Pan WY, Hwang SM, Chang Y, Sung HW. Multimodality noninvasive imaging for assessing therapeutic effects of exogenously transplanted cell aggregates capable of angiogenesis on acute myocardial infarction. Biomaterials. 2015; 73:12-22. doi:10.1016/j.biomaterials.2015.09.009. This is an experimental rat MI study showing that the application of 3D aggregates of HUVECs/cbMSCs improves blood perfusion and global/regional ventricular function. Additionally those aggregates induced increased angiogenesis which was shown in vivo using non-invasive angiogenesis imaging by PET targeting integrin α _v β ₃ and immunohistochemistical stainings.

53.

Hendrikx G, De Saint-Hubert M, Dijkgraaf I, Bauwens M, Douma K, Wierts R, et al. Molecular imaging of angiogenesis after myocardial infarction by (111)In-DTPA-cNGR and (99m)Tc-sestamibi dual-isotope myocardial SPECT. EJNMMI Res. 2015;5:2. doi:10.1186/s13550-015-0081-7.PubMedPubMedCentralCrossRef

54.

Orbay H, Zhang Y, Valdovinos HF, Song G, Hernandez R, Theuer CP, et al. Positron emission tomography imaging of CD105 expression in a rat myocardial infarction model with (64)Cu-NOTA-TRC105. Am J Nucl Med Mol Imaging. 2013;4(1):1–9.PubMedPubMedCentral

55.••

Sun Y, Zeng Y, Zhu Y, Feng F, Xu W, Wu C, Xing B, Zhang W, Wu P, Cui L, Wang R, Li F, Chen X, Zhu Z. Application of (68)Ga-PRGD2 PET/CT for alphavbeta3-integrin imaging of myocardial infarction and stroke. Theranostics. 2014; 4(8):778-786. doi:10.7150/thno.8809. This trial is the first larger trial in humans on angiogenesis after myocardial infarction. It offers an insight into the role of angiogenesis throught myocardial healing after infarction and provides evidence that PET imaging of integrin α _v β ₃ is feasable.

56.•

Melemenidis S, Jefferson A, Ruparelia N, Akhtar AM, Xie J, Allen D, et al. Molecular magnetic resonance imaging of angiogenesis in vivo using polyvalent cyclic RGD-iron oxide microparticle conjugates. Theranostics. 2015;5(5):515–29. doi:10.7150/thno.10319. This study on tumour angiogenesis in mice shows for the first time representative in vivo angiogenesis imaging using RGD-targeted MPIOs in MRI.PubMedPubMedCentralCrossRef

57.••

Notni J, Steiger K, Hoffmann F, Reich D, Kapp TG, Rechenmacher F, Neubauer S, Kessler H, Wester HJ. Complementary, selective PET imaging of integrin subtypes alpha5beta1 and alphavbeta3 using 68Ga-aquibeprin and 68Ga-avebetrin. J Nucl Med. 2016; 57(3):460-466. doi:10.2967/jnumed.115.165720. This trial compares for the first time molecular imaging of myocardial angiogenesis in rat with MI two integrin subtypes. The so far rather neglected integrin α ₅ β ₁ was demonstrated to be more specific for activated endothelial cells with however no decline in affinity.

58.

Dobrucki LW, de Muinck ED, Lindner JR, Sinusas AJ. Approaches to multimodality imaging of angiogenesis. J Nucl Med. 2010. doi:10.2967/jnumed.110.074963.PubMedCentral

59.

Luo BH, Springer TA. Integrin structures and conformational signaling. Curr Opin Cell Biol. 2006;18(5):579–86. doi:10.1016/j.ceb.2006.08.005.PubMedPubMedCentralCrossRef

60.

Humphries MJ. Integrin cell adhesion receptors and the concept of agonism. Trends Pharmacol Sci. 2000;21(1):29–32.PubMedCrossRef

61.

Horton MA. The alpha v beta 3 integrin “vitronectin receptor”. Int J Biochem Cell Biol. 1997;29(5):721–5.PubMedCrossRef

62.

Higuchi T, Bengel FM, Seidl S, Watzlowik P, Kessler H, Hegenloh R, et al. Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res. 2008;78(2):395–403. doi:10.1093/cvr/cvn033.PubMedCrossRef

63.

Bader BL, Rayburn H, Crowley D, Hynes RO. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell. 1998;95(4):507–19.PubMedCrossRef

64.

Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med. 2002;8(1):27–34. doi:10.1038/nm0102-27.PubMedCrossRef

65.

Reynolds AR, Reynolds LE, Nagel TE, Lively JC, Robinson SD, Hicklin DJ, et al. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice. Cancer Res. 2004;64(23):8643–50. doi:10.1158/0008-5472.CAN-04-2760.PubMedCrossRef

66.

Atkinson SJ, Ellison TS, Steri V, Gould E, Robinson SD. Redefining the role(s) of endothelial alphavbeta3-integrin in angiogenesis. Biochem Soc Trans. 2014;42(6):1590–5. doi:10.1042/BST20140206.PubMedCrossRef

67.

Mittra ES, Goris ML, Iagaru AH, Kardan A, Burton L, Berganos R, et al. Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging alpha(v)beta(3) integrin levels. Radiology. 2011;260(1):182–91. doi:10.1148/radiol.11101139.PubMedPubMedCentralCrossRef

68.

Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ, et al. Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med. 2008;49(1):22–9. doi:10.2967/jnumed.107.045864.PubMedCrossRef

69.

Lang L, Li W, Guo N, Ma Y, Zhu L, Kiesewetter DO, et al. Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem. 2011;22(12):2415–22. doi:10.1021/bc200197h.PubMedPubMedCentralCrossRef

70.

Zhu Z, Yin Y, Zheng K, Li F, Chen X, Zhang F, et al. Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using (6)(8)Ga-PRGD2 PET/CT: a prospective proof-of-concept cohort study. Ann Rheum Dis. 2014;73(6):1269–72. doi:10.1136/annrheumdis-2013-204820.PubMedPubMedCentralCrossRef

71.

Chen X, Liu S, Hou Y, Tohme M, Park R, Bading JR, et al. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol. 2004;6(5):350–9. doi:10.1016/j.mibio.2004.06.004.PubMedCrossRef

72.

Lang L, Li W, Jia HM, Fang DC, Zhang S, Sun X, et al. New methods for labeling RGD peptides with bromine-76. Theranostics. 2011;1:341–53.PubMedPubMedCentralCrossRef

73.

Jacobson O, Zhu L, Niu G, Weiss ID, Szajek LP, Ma Y, et al. MicroPET imaging of integrin alphavbeta3 expressing tumors using 89Zr-RGD peptides. Mol Imaging Biol. 2011;13(6):1224–33. doi:10.1007/s11307-010-0458-y.PubMedPubMedCentralCrossRef

74.

Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ, Study G. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692. Acta Radiol. 2010;51(1):40–6. doi:10.3109/02841850903273974.PubMedCrossRef

75.

Jia B, Liu Z, Zhu Z, Shi J, Jin X, Zhao H, et al. Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin alphavbeta3-selective radiotracer 99mTc-3PRGD 2 in non-human primates. Mol Imaging Biol. 2011;13(4):730–6. doi:10.1007/s11307-010-0385-y.PubMedCrossRef

76.

Terry SY, Abiraj K, Frielink C, van Dijk LK, Bussink J, Oyen WJ, et al. Imaging integrin alphavbeta3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts. J Nucl Med. 2014;55(2):281–6. doi:10.2967/jnumed.113.129668.PubMedCrossRef

77.

Sherif HM, Saraste A, Nekolla SG, Weidl E, Reder S, Tapfer A, et al. Molecular imaging of early alphavbeta3 integrin expression predicts long-term left-ventricle remodeling after myocardial infarction in rats. J Nucl Med. 2012;53(2):318–23. doi:10.2967/jnumed.111.091652.PubMedCrossRef

78.

Notni J, Pohle K, Wester HJ. Be spoilt for choice with radiolabelled RGD peptides: preclinical evaluation of (6)(8)Ga-TRAP(RGD)(3). Nucl Med Biol. 2013;40(1):33–41. doi:10.1016/j.nucmedbio.2012.08.006.PubMedCrossRef

79.

Pohle K, Notni J, Bussemer J, Kessler H, Schwaiger M, Beer AJ. 68Ga-NODAGA-RGD is a suitable substitute for (18)F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol. 2012;39(6):777–84. doi:10.1016/j.nucmedbio.2012.02.006.PubMedCrossRef

80.

Gao H, Lang L, Guo N, Cao F, Quan Q, Hu S, et al. PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin targeted tracer (18)F-AlF-NOTA-PRGD2. Eur J Nucl Med Mol Imaging. 2012;39(4):683–92. doi:10.1007/s00259-011-2052-1.PubMedPubMedCentralCrossRef

81.

Dimastromatteo J, Riou LM, Ahmadi M, Pons G, Pellegrini E, Broisat A, et al. In vivo molecular imaging of myocardial angiogenesis using the αvβ3 integrin-targeted tracer 99mTc-RAFT-RGD. J Nucl Cardiol. 2010;17(3):435–43. doi:10.1007/s12350-010-9191-9.PubMedCrossRef

82.

Paeng JC, Bregasi A, Sahul Z, Kalinowski L, Dobrucki LW, Brennan M, et al. Serial reference tissue-based quantitative and volumetric analysis of integrin-targeted angiogenesis imaging: chronic canine model of myocardial infarction. J Nucl Med. 2014;2014(55):1710.

83.

Gaertner FC, Kessler H, Wester HJ, Schwaiger M, Beer AJ. Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 1:S126–38. doi:10.1007/s00259-011-2028-1.PubMedCrossRef

84.

Hu Q, Wang XY, Kang LK, Wei HM, Xu CM, Wang T, et al. RGD-targeted ultrasound contrast agent for longitudinal assessment of Hep-2 tumor angiogenesis in vivo. PLoS One. 2016;11(2):e0149075. doi:10.1371/journal.pone.0149075.PubMedPubMedCentralCrossRef

85.

Shelton SE, Lindsey BD, Tsuruta JK, Foster FS, Dayton PA. Molecular acoustic angiography: a new technique for high-resolution superharmonic ultrasound molecular imaging. Ultrasound Med Biol. 2016;42(3):769–81. doi:10.1016/j.ultrasmedbio.2015.10.015.PubMedCrossRef

86.

Yan F, Xu X, Chen Y, Deng Z, Liu H, Xu J, et al. A lipopeptide-based alphavbeta(3) integrin-targeted ultrasound contrast agent for molecular imaging of tumor angiogenesis. Ultrasound Med Biol. 2015;41(10):2765–73. doi:10.1016/j.ultrasmedbio.2015.05.023.PubMedCrossRef

87.

Leong-Poi H. Molecular imaging using contrast-enhanced ultrasound: evaluation of angiogenesis and cell therapy. Cardiovasc Res. 2009;84(2):190–200. doi:10.1093/cvr/cvp248.PubMedCrossRef

88.

Deng Q, Hu B, Cao S, Song HN, Chen JL, Zhou Q. Improving the efficacy of therapeutic angiogenesis by UTMD-mediated Ang-1 gene delivery to the infarcted myocardium. Int J Mol Med. 2015;36(2):335–44. doi:10.3892/ijmm.2015.2226.PubMedPubMedCentral

89.

Nguyen AT, Wrenn SP. Acoustically active liposome-nanobubble complexes for enhanced ultrasonic imaging and ultrasound-triggered drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014;6(3):316–25. doi:10.1002/wnan.1255.PubMedCrossRef

90.

Fassler R, Meyer M. Consequences of lack of beta 1 integrin gene expression in mice. Genes Dev. 1995;9(15):1896–908.PubMedCrossRef

91.

Tanjore H, Zeisberg EM, Gerami-Naini B, Kalluri R. Beta1 integrin expression on endothelial cells is required for angiogenesis but not for vasculogenesis. Dev Dyn. 2008;237(1):75–82. doi:10.1002/dvdy.21385.PubMedCrossRef

92.

Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol. 2000;156(4):1345–62.PubMedPubMedCentralCrossRef

93.

Corti A, Curnis F, Arap W, Pasqualini R. The neovasculature homing motif NGR: more than meets the eye. Blood. 2008;112(7):2628–35. doi:10.1182/blood-2008-04-150862.PubMedPubMedCentralCrossRef

94.

Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood. 2001;97(3):652–9.PubMedPubMedCentralCrossRef

95.

Buehler A, van Zandvoort MA, Stelt BJ, Hackeng TM, Schrans-Stassen BH, Bennaghmouch A, et al. cNGR: a novel homing sequence for CD13/APN targeted molecular imaging of murine cardiac angiogenesis in vivo. Arterioscler Thromb Vasc Biol. 2006;26(12):2681–7. doi:10.1161/01.ATV.0000245807.65714.0b.PubMedCrossRef

96.

Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279(5349):377–80.PubMedCrossRef

97.

Fonsatti E, Sigalotti L, Arslan P, Altomonte M, Maio M. Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Curr Cancer Drug Targets. 2003;3(6):427–32.PubMedCrossRef

98.

Hong H, Zhang Y, Orbay H, Valdovinos HF, Nayak TR, Bean J, et al. Positron emission tomography imaging of tumor angiogenesis with a (61/64)Cu-labeled F(ab’)(2) antibody fragment. Mol Pharm. 2013;10(2):709–16. doi:10.1021/mp300507r.PubMedPubMedCentralCrossRef

99.

Zhang Y, Hong H, Severin GW, Engle JW, Yang Y, Goel S, et al. ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW. Am J Transl Res. 2012;4(3):333–46.PubMedPubMedCentral

100.

Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci. 2008;121(20):3487–95. doi:10.1242/jcs.016410.PubMedPubMedCentralCrossRef

101.

Li S, Peck-Radosavljevic M, Koller E, Koller F, Kaserer K, Kreil A, et al. Characterization of 123I-vascular endothelial growth factor–binding sites expressed on human tumour cells: Possible implication for tumour scintigraphy. Int J Cancer. 2001;91(6):789–96. doi:10.1002/1097-0215(200002)9999:9999<::AID-IJC1126>3.0.CO;2-K.PubMedCrossRef

Title: Molecular Imaging of Angiogenesis in Cardiac Regeneration
Authors: Ljubica Mandic
Denise Traxler
Alfred Gugerell
Katrin Zlabinger
Dominika Lukovic
Noemi Pavo
Georg Goliasch
Andreas Spannbauer
Johannes Winkler
Mariann Gyöngyösi
Publication date: 01-10-2016
Publisher: Springer US
Published in: Current Cardiovascular Imaging Reports / Issue 10/2016
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI: https://doi.org/10.1007/s12410-016-9389-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Molecular Imaging of Angiogenesis in Cardiac Regeneration

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page